/
CRVO
$3.15-$0.34 (-9.74%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$32.3M
9M shares
52-week range
$2.13 – $13.13
9% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
381.41%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-4.44
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $110.4K | $97.9K | $103.2K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$110.0K | −$97.9K | −$103.2K | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $5.8M | $6.6M | $9.4M | $8.5M | $1.3M | $8.4M | $18.8M | $21.8M |
| Operating income | −$12.0M | −$11.6M | −$16.0M | −$24.7M | −$3.5M | −$7.8M | −$18.2M | −$28.3M |
| EBITDA | −$18.7M | −$11.4M | −$15.8M | −$15.9M | −$5.8M | −$2.2M | −$16.3M | −$27.0M |
| Net income | −$18.4M | −$11.8M | −$14.2M | −$24.1M | −$5.8M | −$2.2M | −$16.3M | −$27.0M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -424.93 | -131.95 | -22.50 | -18.51 | -11.20 | -0.82 | -2.02 | -2.98 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $228571 | $-2.70 | $-4.09–$-1.65 | 5 |
| 2027 | $833333 | $-2.46 | $-2.67–$-2.23 | 4 |
| 2028 | $1M | $-2.33 | $-3.41–$-1.21 | 3 |
| 2029 | $7M | $-1.43 | $-1.43–$-1.43 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.80
Price
$3.15
Implied downside
-75%
Peer comparison
CervoMed Inc. Common Stock
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
www.cervomed.com- Employees
- 15
- IPO / List date
- Jun 18, 1996
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds CRVO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 63,904 | $251.8K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2022-04-19 | 1-for-50reverse |
| 2018-12-14 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded CRVO yet.
